Fatty liver
Drug research and approvals for fatty liver: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 279 studies of fatty liver are recruiting on ClinicalTrials.gov, Health Canada has authorized 9 drug trials for it since 2013, FDA has 0 approved and 1 open orphan designations naming it, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 279
- Trials authorized in Canada: 9
- FDA orphan approvals: 0
- EU medicines: 2
- High-Plant-Protein-Diet or High-Animal-Protein-Diet for Improving Alcoholic Fatty Liver DiseaseNCT07897981 · Phase 1 / Phase 2 · Li Lab,MD · starts Oct 10, 2026
- Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLDNCT07877272 · Not reported · University Hospital Muenster · starts Oct 5, 2026
- Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)NCT07854782 · Phase 3 · Regeneron Pharmaceuticals · starts Oct 28, 2026
- Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 FibrosisNCT07848191 · Phase 4 · Madrigal Pharmaceuticals, Inc. · starts Oct 7, 2026
- Metaboic Syndrome and Fatty Liver in Celiac Disease Females: Reponse to Exercise in AdolescentsNCT07832994 · Not applicable · Cairo University · starts Aug 15, 2026
- Resmetirom in Patients With MASH and HFpEFNCT07830758 · Phase 1 · Madrigal Pharmaceuticals, Inc. · starts Oct 16, 2026
- NMR Metabolomics-Based Risk Assessment and Stratified Digital Health Interventions in Middle-Aged Adults (PREMAP)NCT07820800 · Not applicable · University of Eastern Finland · starts Sep 1, 2026
- A Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal ImpairmentNCT07807059 · Phase 1 · Fujian Shengdi Pharmaceutical Co., Ltd. · starts Sep 9, 2026
- Phase 1 Clinical Study of MWN105 Injection in Participants With Overweight or ObesityNCT07803809 · Phase 1 · Shanghai Minwei Biotechnology Co., Ltd · starts Apr 26, 2026
Phase 3 7
- Vitamin e
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- PioglitazonePeroxisome proliferator-activated receptor gamma agonist
- RimonabantCannabinoid CB1 receptor antagonist
- DapagliflozinSodium/glucose cotransporter 2 inhibitor
- SaroglitazarPeroxisome proliferator-activated receptor alpha agonist
- Omega-3 fatty acids
Phase 2 7
- SpironolactoneMineralocorticoid receptor antagonist
- PentoxifyllineAdenosine A2 receptor antagonist
- Cholic acid
- CannabidiolCannabinoid CB1 receptor negative allosteric modulator
- Icosapent
- Fish oilSupplement
- Icomidocholic acid
Phase 1 or earlier 8
- CilostazolPhosphodiesterase 3A inhibitor
- EsomeprazolePotassium-transporting ATPase inhibitor
- CysteamineCystine reducing agent
- Omega-3-ACID ethyl esters
- Lactobacillus acidophilusProbiotic
- Ginger
- Acetic acid
- D-limonene
How its trials ended
1,576 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 318 whose ending is known, 48% met their primary endpoint, 9% missed it and 43% stopped early.
- Completed, result not reported58337%
- Ongoing42527%
- Status unknown25016%
- Met its primary endpoint15210%
- Stopped: other or unclear664%
- Stopped: enrollment or feasibility292%
- Missed its primary endpoint282%
- Stopped: sponsor or business decision191%
- Stopped: lack of efficacy171%
- Stopped: funding6<1%
- Stopped: safety1<1%
| Mar 28, 2025 | Stimulating adipose tissue fatty acid disposal with low-dose, postprandial, intermittent niacin for the treatment of metabolic dysfunction-associated steatotic…Nicotinic acid / Albumin / 11C palmitate / 18F ftha | Ciusss De L'Estrie - Centre Hospitalier Universitaire De Sherbrooke | Pending |
| Mar 7, 2025 | A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of denifanstat in patients with metabolic dysfunction…Denifanstat (TVB-2640) | Sagimet Biosciences | Closed |
| Sep 12, 2023 | A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of efruxifermin in subjects with non-invasively diagnosed…Efruxifermin (EFX) | Akero Therapeutics | Ongoing |
| Jan 20, 2023 | A phase 1b study of QX1206 in type 2 diabetes mellitus (T2DM) patients with non-alcoholic fatty liver disease (NAFLD)Amcasertib (QX1206) | 1Globe Health Institute | Ongoing |
| Jul 13, 2021 | A phase 2a, randomized, active-comparator-controlled, open-label study to evaluate the efficacy and safety of efinopegdutide (MK-6024) in individuals with…Efinopegdutide (MK-6024)/ Semaglutide | Merck & Co. (MSD) | Closed |
| Jun 18, 2021 | A randomized, double-blind, placebo-controlled, dose ranging study to evaluate the safety, tolerability, and efficacy of AXA1125 in subjects with…AXA1125 | Axcella Health | Ongoing |
| Jul 10, 2019 | A phase 2, randomized, double-blind, placebo-controlled, multicenter, dose-finding study to evaluate the efficacy and safety of CC-90001 in subjects with…CC-90001 | Bristol-Myers Squibb | Closed |
| Jul 4, 2019 | A phase 2a, randomized, double-blind, placebo-controlled, 3-arm, parallel group study to evaluation safety, tolerablity and pharmacodynamics of PF-06835919…PF-06835919 | Pfizer | Closed |
| Aug 29, 2017 | An adaptive design study for the assessment of the safety, tolerability, and pharmacokinetics of RYI-018 after repeat dosing in subjects with non-alcoholic…RYI-018 | Bird Rock Bio, Inc | Pending |
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Mar 28, 2018 | FluasteroneTreatment of Cushing syndrome (including hyperglycemia, nonalcoholic fatty liver disease, and nonalcoholic steatosis) | Sterotherapeutics, LLC | Designated |
| Mar 26, 2026 | KayshildSemaglutide | Novo Nordisk A/S | EMA ↗ |
| Aug 18, 2025 | RezdiffraResmetirom | Madrigal Pharmaceuticals EU Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA